CABO GIST


CABO GIST

Agents: Cabozantinib
Phase II
Status  Open, recruiting
Sponsor EORTC

 

Further information: https://clinicaltrials.gov/ct/show/NCT02216578 or http://www.eortc.org/research_field/clinical-detail/1317/

 

WHO is the trial for?

  • Patients with metastatic GIST (histologically confirmed) and removed primary tumor
  • Patients with progression during treatment of GIST (before or after surgery, with or without metastasis) with imatinib and sunitinib (but no further/other therapies)
  • Overall health status of the patient has to be good (ECOG performance status 0-1)
  • Tumor tissue samples need to be available from primary tumor or metastasis for mutational analysis
  • Adequate bone marrow, heart and other organ function

WHAT is the key question that this trial is attempting to answer?

This study assesses the safety and activity of cabozantinib in patients with metastatic GIST who have previously progressed on imatinib and sunitinib

WHY patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in GIST and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN will the trial be open?

The study is open (recruiting)

WHERE is the trial available?

The trial will be available in several study centers in Belgium, the Czech Republic, France, Germany, Hungary and the UK. For a complete list of trial locations, please see here (trial number 1317).

Study contact:
Contact: Ward Sents, EORTC Headquarters, Brussels
Phone: +32 27741533
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

STUDY DESIGN: What does the study look like?

There will be only one study arm (group): all participating patients will be receiving the new drug.

 

SPAEN Study Registry CABO GIST Design

HOW do I get more information?

Patient organisations supporting GIST and/or sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving GIST and/or sarcoma patients. If there are no such organisation in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE your experience

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

No results are available at this time. Future results will be linked here.


Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken